anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Kaempferol (KA), an natural antioxidant of traditional Chinese medicine (TCM), is extensively used as the primary treatment for inflammatory digestive diseases with impaired redox homeostasis. Severe acute pancreatitis (SAP) was exacerbated by mitochondrial dysfunction and abundant ROS, which highlights the role of antioxidants in targeting mitochondrial function. However, low bioavailability and high dosage of KA leading to unavoidable side effects limits clinical transformation. The mechanisms of KA with poor bioavailability largely unexplored, hindering development of the efficient strategies to maximizing the medicinal effects of KA. Here, we engineered a novel thioketals (TK)-modified based on DSPE-PEG2000 liposomal codelivery system for improving bioavailability and avoiding side effects (denotes as DSPE-TK-PEG2000-KA, DTM@KA NPs). We demonstrated that the liposome exerts profound impacts on damaging intracellular redox homeostasis by reducing GSH depletion and activating Nrf2, which synergizes with KA to reinforce the inhibition of inadequate fission, excessive mitochondrial fusion and impaired mitophagy resulting in inflammation and apoptosis; and then, the restored mitochondrial homeostasis strengthens ATP supply for PAC renovation and homeostasis. Interestingly, TK bond was proved as the main functional structure to improve the above efficacy of KA compared with the absence of TK bond. Most importantly, DTM@KA NPs obviously suppresses PAC death with negligible side effects in vitro and vivo. Mechanismly, DTM@KA NPs facilitated STAT6-regulated mitochondrial precursor proteins transport via interacting with TOM20 to further promote Drp1-dependent fission and Pink1/Parkin-regulated mitophagy with enhanced lysosomal degradation for removing damaged mitochondria in PAC and then reduce inflammation and apoptosis. Generally, DTM@KA NPs synergistically improved mitochondrial homeostasis, redox homeostasis, energy metabolism and inflammation response via regulating TOM20-STAT6-Drp1 signaling and promoting mitophagy in SAP. Consequently, such a TCM's active ingredients-based nanomedicine strategy is be expected to be an innovative approach for SAP therapy.
BACKGROUND: Second branchial cleft cyst (2nd BCC) is treated by complete excision. Conventional transcervical skin incision on the lesion may leave a prominent scar in the cosmetically sensitive area. The retroauricular hairline incision (RAHI) approach may maintain neurological, mobility, and cosmetic functions of the neck and face after excision. This study evaluated the clinical outcomes and disease control of scarless surgery via RAHI in 57 consecutive patients with 2nd BCC.
METHODS: The patients received the prospective evaluation of postoperative neurological, subjective pain, swallowing, neck motion, and cosmetic functions. Postoperative complications, subjective satisfaction, and recurrence were also assessed in each patient.
RESULTS: Excision was performed in all cases without injury to the facial nerve or other neurological complications and conversion to other incisions or approaches with a median operation time of 44 min. Complications were minimal, without dysphagia, neurological deficits, or limited neck motion. Postoperative incision scars in the postauricular and hairline region were commonly invisible. Subjective satisfaction with the scar and facial deformity was high after surgery. No patients had a recurrence for a median follow-up of 66 months.
CONCLUSION: The RAHI approach for 2nd BCC has excellent cosmetic, functional, and disease control outcomes. This can be safely applied to the treatment of 2nd BCC.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
FIELD: cosmetic and pharmaceutical industry.SUBSTANCE: invention relates to the cosmetic and pharmaceutical industry and namely to making products for the care of the oral cavity. The proposed method involves mixing the active substance with auxiliary components. In this case, enzymatic hydrolysates of coconut oil in an amount of 0.25-2.5 wt.% are used as an active ingredient. They are obtained as a result of hydrolysis of coconut oil with the help of a lipase from a pork stomach Type II with an activity of 100-500 units/mg of protein at a temperature of 37C and a pH of 7.7. Hydrolysis lasted for a period from 4 to 24 hours and was accompanied by chromatographic separation of palmitic and oleic acid residues from the hydrolyzate. Sodium fluoride, sodium lauryl sulfate, a flavouring agent and water are used as auxiliary components.EFFECT: invention provides a new method of obtaining a bactericidal agent based on hydrolysates of coconut oil for oral care aimed at preventing caries and other diseases of the oral cavity caused by microorganisms.5 cl, 2 tbl, 4 ex
PURPOSE: Provided are a composition for preventing depilation and promoting hair growth and the use thereof. The composition is manufactured by using ginseng, Cynanchum wilfordii (MAX.) HEMSL., Angelica uchiyamana, Astragalus membranaceus, Carthamus tinctorius, Achyranthes japonica (MIQ.) NAKAI., and Eucommia ulmoides as main ingredients. CONSTITUTION: A composition for preventing depilation and promoting hair growth is manufactured by extracting 5-30 part by weight of ginseng, 15-40 part by weight of Cynanchum wilfordii (MAX.) HEMSL., 5-20 part by weight of Angelica uchiyamana, 5-20 part by weight of Astragalus membranaceus, 5-30 part by weight of Carthamus tinctorius, 2-20 part by weight of Achyranthes japonica (MIQ.) NAKAI., and 5-10 part by weight of Eucommia ulmoides with 6-10 times of hot water of 60-100 deg.c or lower alcohol; and purifying and spray- or freeze-drying the extract.
BACKGROUND AND AIMS: Accurate biomarkers to predict outcomes following discontinuation of nucleos(t)ide analogue (NA) therapy are needed. We evaluated serum hepatitis B core-related antigen (HBcrAg) level as a biomarker for predicting outcomes after NA discontinuation.
METHODS: Patients with HBeAg-negative chronic hepatitis B (CHB) without cirrhosis were enrolled in a prospective trial evaluating clinical outcomes until 96 weeks after NA discontinuation. End of treatment (EOT) and off-treatment levels of serum HBcrAg, HBsAg, HBV RNA and HBV DNA were used to predict key clinical outcomes including hepatitis flare (ALT ≥5 × ULN and HBV DNA > 2000 IU/mL). The SCALE-B score was calculated for the purposes of model validation.
RESULTS: HBcrAg was tested amongst 65 participants. The median age was 54 years, 54% were male and 83% were Asian. HBcrAg was detectable in 86% patients. HBcrAg level ≥4 log U/mL at EOT was predictive of hepatitis flare [8/10 (80%) vs. 17/55 (31%), p = .001]. The presence of either HBcrAg ≥4 log U/mL or detectable HBV RNA at EOT predicted for both biochemical relapse and hepatitis flare. The SCALE-B model at EOT predicted for virological relapse, biochemical relapse, hepatitis flare and HBsAg loss in this cohort. An increase in the serum HBcrAg level off-treatment was also associated with hepatitis flare. No participant with EOT HBcrAg level ≥4 log U/mL achieved HBsAg loss.
CONCLUSIONS: High levels of serum HBcrAg predict for hepatitis flare after stopping NA therapy and low likelihood of HBsAg loss at week 96. People with high levels of serum HBcrAg are not suitable candidates for NA discontinuation.
This cohort includes patients diagnosed with stage I-IV colorectal cancer (CRC) who have undergone curative surgery. Inclusion criteria: patients aged 18 years or older, histologically confirmed CRC, no prior history of malignancy, availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood), and primary tumor tissue samples. Patients must not have received neoadjuvant therapy before surgery and must have complete follow-up data. Exclusion criteria: prior history of other malignancies, incomplete clinical information or pathology reports, and incomplete follow-up records. The study aims to identify specific biomarkers associated with CRC recurrence and metastasis through comprehensive multi-omics sequencing and develop predictive models for CRC recurrence and metastasis.
One or more instruments generate test result data. The test result data include patient data and QC data. The test result data is provided to a QC data flow system via a local network, which filters the test result data (e.g., using a set of rules) to extract the QC data. The QC data is provided to a cloud-based QC data management platform via an external network. The cloud-based QC data management platform analyzes the QC data and provides a result back to the QC data flow system. The QC data flow system forwards the result to middleware or the instrument, which triggers a corrective action based on the result as appropriate.
CASE HISTORY AND CLINICAL FINDINGS: An approximately 10-year-old, castrated male domestic short-haired cat developed swelling and ulceration of the second digit of the right front paw. Radiographs revealed a spherical soft tissue swelling with irregular distal margins that contained multiple lacy mineral opacities. The digit was amputated and submitted for histology. No recurrence has been observed 7 months after amputation.
PATHOLOGICAL AND MOLECULAR FINDINGS: Histology revealed a moderately well-circumscribed proliferation of well-differentiated squamous cells arranged in trabeculae and nests. Numerous thin spicules of osseous metaplasia were visible throughout the neoplasm. Around 70% of the neoplastic cells contained papillomavirus-induced cell changes including large amphophilic cytoplasmic bodies and cells with shrunken nuclei surrounded by a clear halo. Intense p16CDKN2A protein immunostaining was visible within the neoplastic cells, suggesting papillomavirus-induced changes in cell regulation. A DNA sequence from a putative novel Taupapillomavirus type was amplified from the neoplasm.
DIAGNOSIS: Osteoinductive squamous cell carcinoma associated with a putative novel papillomavirus type.
CLINICAL RELEVANCE: The findings in this case increase the number of papillomavirus types known to infect cats, and the squamous cell carcinoma had histological features that have not been previously reported. The neoplasm was not as invasive as is typical for a squamous cell carcinoma and excision appeared curative. This is the first report of an osteoinductive squamous cell carcinoma of the skin of cats and the neoplasm had a unique radiographic appearance.
Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE: To obtain an excellent temporarily coloring hair, substantially free from discoloration under the sunlight and resistant to rubbing out and washing out when it comes to contact with water by combining a water-soluble melamine produced by chemical or biological synthesis with a water-dispersible cationic substance. CONSTITUTION: A composition for temporarily coloring hair obtained by combining a water-soluble melamine produced by chemical or biological synthesis with a water-dispersible cationic substance. The water-soluble melamine preferably has an anionic property. Further, the anionic water-soluble melamine preferably forms a complex with a water-dispersible cationic substance. Preferable examples of the water-dispersible cationic substance include dicetyldimonium chloride, Merquat 100, Merquat 3330 and Polyquaternium 11. The composition may be compounded with a cosmetically permissible carrier, solvent, solubilizer, thickener, alkalizing agent, chelating reagent, preservative or flavoring agent. The composition is less expensive, resistant to soiling the skin and easily applicable.
Participants in this group will receive Cognitive Behavioral Therapy, which involves identifying and modifying negative thought patterns and behaviors to alleviate symptoms of depression and anxiety. Therapy sessions are conducted in person and on a one-on-one basis, ensuring tailored and direct therapeutic engagement. Each participant will attend 12 weekly sessions, each lasting approximately one hour.
The invention provides a helicobacter pylori tetravalent virulence factor multi-epitope vaccine and a preparation method thereof. The active constituent of the vaccine is polypeptide. The vaccine mainly comprises the dominant Th and B cell epitopes or sections of a urease A subunit, a urease B subunit, cytotoxin associated protein A and vacuolating cytotoxin associated protein A, and neutrophil activating protein. The gene synthesis and molecular cloning technology is used for building a fused gene containing the dominant Th and B cell epitopes or sections of ureases, the cytotoxin associated protein A and the vacuolating cytotoxin associated protein A, and the neutrophil activating protein. Escherichia coli is used for expressing the fused gene, and the tetravalent virulence factor multi-epitope vaccine is obtained after protein purification. The vaccine can stimulate a body to generate T cell immunity response and specific antibody humoral immunity response aiming at the ureases, the cytotoxin associated protein A, the vacuolating cytotoxin associated protein A and the neutrophil activating protein and can be used for preventing and treating diseases related to helicobacter pylori infection.
Only ~20% of heavy drinkers develop alcohol cirrhosis (AC). While differences in metabolism, inflammation, signaling, microbiome signatures and genetic variations have been tied to the pathogenesis of AC, the key underlying mechanisms for this interindividual variability, remain to be fully elucidated. Induced pluripotent stem cell-derived hepatocytes (iHLCs) from patients with AC and healthy controls differ transcriptomically, bioenergetically and histologically. They include a greater number of lipid droplets (LDs) and LD-associated mitochondria compared to control cells. These pre-pathologic indicators are effectively reversed by Aramchol, an inhibitor of stearoyl-CoA desaturase. Bioenergetically, AC iHLCs have lower spare capacity, slower ATP production and their mitochondrial fuel flexibility towards fatty acids and glutamate is weakened. MARC1 and PNPLA3, genes implicated by GWAS in alcohol cirrhosis, show to correlate with lipid droplet-associated and mitochondria-mediated oxidative damage in AC iHLCs. Knockdown of PNPLA3 expression exacerbates mitochondrial deficits and leads to lipid droplets alterations. These findings suggest that differences in mitochondrial bioenergetics and lipid droplet formation are intrinsic to AC hepatocytes and can play a role in its pathogenesis.
This is a double-blinded randomized controlled trial to take place in the Vidant Medical Center (VMC) Emergency Department (ED). A convenience sample of 96 participants will be drawn from patients presenting to the ED presentation with pain associated with suspected renal colic who do not experience pain relief after initial treatment with nonsteroidal anti-inflammatories.

Written informed consent will be sought by a study team member after screening to ensure all inclusion criteria and no exclusion criteria are met. Once a patient has consented, they will be randomized into 1 of 2 study arms: Arm 1 (Control arm) = 0.1mg/kg of intravenous morphine + placebo pill, single dose Arm 2 (Study arm) = 0.05mg/kg intravenous morphine + 0.25mg pramipexole, single dose. Both arms include a maximum dose of 10mg/kg for the IV morphine. Pain scores will be obtained prior to administration of study drugs, and at 15-minute intervals (+/- 2 mins) after treatment for up to 2 hours, or discharge from the ED. Subjective response to each drug treatment will also be assessed every 15 minutes (+/- 2 mins) after treatment for up to 2 hours, or discharge from ED. Morphine will have a max dose of 10mg IV.
The study will enroll healthy adult subjects with a minimum of two cutaneous non-genital warts, excluding the face, with each wart lesion not exceeding 10 x 10mm. One of the warts for each subject will be untreated and will serve as the subject's internal control. Macrophotography of all study warts will be captured along with Investigator assessments using the Wart Measurement Scale (WMS) and lesion measurements for wart reduction. All subjects will be followed at 7, 30, 60, 90 and 120-days post-initial CellFX treatment. All wart lesions are eligible for re-treatment up to 3 times over the course of the study. Adverse events will be documented.
The invention relates to Indian kalimeris-containing medicines, healthcare food and oral-nasal sanitary products, and particularly relates to medicines treating rhinitis, nasosinusitis, arthralgia, tinea, astriction, mouth mucositis, hypertension, insomnia and acne, healthcare food relieving physical fatigue, protecting liver, reducing blood pressure, achieving antimicrobial effects, diminishing inflammation, clearing throat, achieving antioxidant, anti-ageing and anticancer effects, removing acne, relaxing the bowels, increasing the bone density, promoting digestion, protecting gastric mucosa and improving sleep, and oral-nasal sanitary products. The Indian kalimeris is fully extracted at low temperature and is dried at low temperature to obtain solid powder. 3 g of the powder is used for each time, water is added to dissolve the powder until the weight of the mixture is 10 g, rhinitis and nasosinusitis can be treated by dripping the mixture into nose (for one time a day and 2-7 days successively), and gingival bleeding, gingiva inflammation and dental ulcer can be prevented and improved by rinsing the mouth with the mixture daily. When water is added to dissolve the powder until the weight of the mixture is 50 g, meatus nasopharyngeus can be cleaned and meatus nasopharyngeus diseases can be prevented by daily washing the nose with the mixture. When the powder is taken after the powder is brewed with boiling water, treatment of abovementioned diseases and abovementioned healthcare can be achieved (with the powder being taken 1-3 times a day or for a long term). Effects are significant. Other components can be added.
This protocol was designed to determine the optimum position of the gaze for pneumatic displacement of subretinal hemorrhage (SRH) in the macula. A geometrical analysis of the forces that act upon a SRH in the presence of an intraocular gas bubble was analyzed and it was concluded that the displacement was due to the effect of gravity on the SRH immersed in gas. This was followed by a prospective trial of positions of gaze and volumes of gas calculated to be optimum for displacement. The eyes of consecutive patients with SRH in the macula will had an intravitreal injection of pure perfluorocarbon gas sufficient to provide a 40% bubble after expansion. The patients are instructed to gaze down 40° or 60° below the horizontal depending on the volume of gas for 20 minutes every hour. The SRH is displaced rapidly in the first week. Visual acuity usually improves but recovery can be limited by the presence of sub pigment epithelial hemorrhage, exudate or proliferation. A vector of the gravity force tangential to the sclera is the largest force acting to displace a subretinal hemorrhage within a gas bubble. 79% of the vertical gravity component is obtained at gaze 40° below the horizontal and requires volumes of intraocular gas not requiring prior removal of vitreous. Face down positioning in common practice has been an error and succeeds only if the patient has been non compliant.

5- STATUS
This invention relates to a method for preparing metadoxine. The method comprises: adding isopropanol to mixed solid powder of vitamin B6 alkali and pyroglutamic acid, reacting at 25-45 deg.C for 30 min-24 h, filtering, and drying the solid to obtain metadoxine. The mol. ratio of vitamin B6 alkali to pyroglutamic acid is 1:1. The weight ratio of pyroglutamic acid to isopropanol is 1 :( 1.0-4). The content of deionized water in isopropanol is 0-5%. The method has such advantages as no need for refinery, low solvent consumption, low cost, simple process, easy operation and high yield, and is suitable for industrialization. The obtained drug-grade metadoxine can be used to treat acute and chronic alcoholism and alcoholic liver disease.
A process and device are claimed for the cosmetic partial or complete lightening of hair colour. Hair is irradiated a lock at a time by passing through a laser beam strong enough to degrade the melamine in the hair, but not so strong that the keratin is damaged. Keratin in dark hair is degraded at a lower energy density than that in naturally light hair. Several irradiation passes are made on each lock of hair until the desired colour is achieved. The laser used has an energy density of 0.1-1.2 J/cm<2> at a wavelength of 532 nm. The energy density used varies, proportional to the wavelength.
Acanthamoeba keratitis is a rare eye infection that is difficult to treat. The mainstay of therapy is a biguanide agent such as chlorhexidine, though recent studies have found povidone iodine to be effective for killing acanthamoeba organisms in vitro. Thus, we randomize participants to topical chlorhexidine 0.04% monotherapy (i.e., routine care) versus topical chlorhexidine 0.04% plus topical poviodine iodine 2.5%. The primary outcome is clearance of acanthamoeba from the ocular surface at 4 weeks.

The role of topical corticosteroids in acanthamoeba keratitis is controversial. Topical corticosteroids can promote growth of acanthamoeba, but may also reduce inflammation and vision-threatening complications of infection. Here, we randomize participants who have completed a course of anti-amoebic therapy to one of three groups: early prednisolone sodium phosphate 1% (started at 4 weeks), late prednisolone sodium phosphate 1% (started at 6 weeks) or placebo (started at 4 weeks). The primary outcome will be visual acuity at 6 months.
Falls and chronic respiratory are two major health concerns affecting morbidity and mortality in older adults. Several factors that predispose falls, such as reduced balance, have been documented in people with respiratory disease. Pulmonary rehabilitation programs, which involve customized exercise prescription, are recommended to improve quality of life and disease management in people with chronic obstructive pulmonary disease (COPD). There are many documented benefits to participation in such programs; however, the impact on balance and other falls risk factors has not previously been investigated. Therefore, the aim of this study is to investigate the effect of a pulmonary rehabilitation program on balance and falls risk factors in individuals with respiratory disease. This study will enhance the current management of respiratory disease by improving our understanding of the effects of pulmonary rehabilitation.